Lymphomas are heterogeneous tumors with striking genetic diversity and variable outcomes
even within pathologic diagnoses. Treatment response assessment relies on radiologic and …

Simple Summary Even though the presently employed biomarkers in the detection and
management of multiple myeloma are demonstrating encouraging results, the mortality …

Simple Summary Monitoring the response to treatment in hematologic malignancies is
essential in defining the best way to optimize patient management. In general, achieving a …

Simple Summary Liquid biopsy is a diagnostic procedure in which a blood sample taken
from a cancer patient is searched for cell-free DNA that originates from tumor cells in the …

The rapid evolution of genomic technologies over the last years has led to the development
of different methods for the detection, measurement and analysis of cell-free DNA fragments …

Epstein–Barr virus (EBV) infection is proved to be associated with clinicopathology of
lymphoma. However, little is known about the relationship between EBV‐DNA status after …

Cell-free DNA (cfDNA) is a fragment of DNA circulating in the blood, and its concentration is
often elevated in cancer patients. To investigate the relationships between serum cfDNA …

Simple Summary Liquid biopsy (LBx) is a novel and promising approach in precision
medicine, suitable for patient management in a wide range of medical conditions. Its utility in …

Simple Summary It is well known that epigenetic modifications and proteins involved in this
process are important in the biogenesis of diffuse large B-cell lymphoma. In this sense, we …

The utility of circulating tumor DNA (ctDNA) in classifying the cell origin of diffuse large B-cell
lymphoma (DLBCL) has not been explored in the Chinese population. In this study, we …